Amgen loses battle against Colorado over drug affordability board

What's new in pharma

March 28, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mark J. Terrill/AP STAT+ | Amgen loses its battle against Colorado over a prescription drug affordability board Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business outside of Colorado. By Ed Silverman STAT+ | Novo Nordisk sets sights on new type of oral obesity drug The Danish drugmaker is licensing a drug from Lexicon Pharmaceuticals that may help patients maintain their weight loss when they stop taking GLP-1s. By Allison DeAngelis and Elaine Chen STAT+ | Two of FDA's top cancer regulators to depart, heightening worries about drug reviews Deputy directors at the FDA center that oversees the regulation of cancer drugs plan to leave, adding to a flood of top talent in recent months. By Matthew Herper Sarah Silbiger/Getty Images STAT+ | RFK Jr. brings FDA under tighter control with HHS workforce cuts FDA cuts called 'too big, too fast' are part of a HHS reorganization that gives RFK Jr. more control over the agency, workers anxiously await their fate. By Lizzy Lawrence, Sarah Todd, and Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser